Literature DB >> 16402083

Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms.

S Ide1, H Kobayashi, H Ujike, N Ozaki, Y Sekine, T Inada, M Harano, T Komiyama, M Yamada, M Iyo, N Iwata, K Tanaka, H Shen, K Iwahashi, M Itokawa, M Minami, M Satoh, K Ikeda, I Sora.   

Abstract

Several studies indicate that the mu-opioid receptor plays a role in addiction not only to opiate drugs but also to alcohol and non-opiate addictive drugs. Our studies aim to reveal the associations between gene polymorphisms and methamphetamine (MAP) dependence/psychosis. We newly identified several polymorphisms and four substantial linkage disequilibrium (LD) blocks in the mu-opioid receptor (OPRM1) gene. We found significant differences in both genotype and allele frequencies of the single-nucleotide polymorphism (SNP) IVS2+G691C between control (n=232) and MAP-dependent/psychotic patients (n=128). There was also a significant association between IVS2+G691C and patients with transient psychosis. These results suggest that the OPRM1 gene variations may be a factor in development and prognosis of MAP psychosis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16402083     DOI: 10.1038/sj.tpj.6500355

Source DB:  PubMed          Journal:  Pharmacogenomics J        ISSN: 1470-269X            Impact factor:   3.550


  19 in total

Review 1.  Candidate gene polymorphisms predicting individual sensitivity to opioids.

Authors:  Shinya Kasai; Masakazu Hayashida; Ichiro Sora; Kazutaka Ikeda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  A functional polymorphism of the micro-opioid receptor gene is associated with completed suicides.

Authors:  A Hishimoto; H Cui; K Mouri; H Nushida; Y Ueno; K Maeda; O Shirakawa
Journal:  J Neural Transm (Vienna)       Date:  2008-02-04       Impact factor: 3.575

Review 4.  Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.

Authors:  Colin N Haile; Thomas R Kosten; Therese A Kosten
Journal:  Am J Drug Alcohol Abuse       Date:  2009       Impact factor: 3.829

Review 5.  Genetic factors modulating the response to stimulant drugs in humans.

Authors:  Amy B Hart; Harriet de Wit; Abraham A Palmer
Journal:  Curr Top Behav Neurosci       Date:  2012

6.  Morphine intake and the effects of naltrexone and buprenorphine on the acquisition of methamphetamine intake.

Authors:  E C Eastwood; T J Phillips
Journal:  Genes Brain Behav       Date:  2013-11-18       Impact factor: 3.449

7.  Genetic factors involved in risk for methamphetamine intake and sensitization.

Authors:  John K Belknap; Shannon McWeeney; Cheryl Reed; Sue Burkhart-Kasch; Carrie S McKinnon; Na Li; Harue Baba; Angela C Scibelli; Robert Hitzemann; Tamara J Phillips
Journal:  Mamm Genome       Date:  2013-11-13       Impact factor: 2.957

Review 8.  OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

Authors:  Stephen D Mague; Julie A Blendy
Journal:  Drug Alcohol Depend       Date:  2010-01-13       Impact factor: 4.492

Review 9.  Biological treatments for amfetamine dependence : recent progress.

Authors:  Kevin P Hill; Mehmet Sofuoglu
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  OPRM1 gene variants modulate amphetamine-induced euphoria in humans.

Authors:  A M Dlugos; A Hamidovic; C Hodgkinson; P H Shen; D Goldman; A A Palmer; H de Wit
Journal:  Genes Brain Behav       Date:  2010-11-02       Impact factor: 3.449

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.